Boosting Digital Fortresses: Broadcom & Google Cloud Partner To Boost Cybersecurity With AI

Broadcom Inc's (NASDAQ: AVGO) division Symantec announced a collaboration with Alphabet Inc. (NASDAQ: GOOGL) (NASDAQ: GOOG) Google C

Broadcom Inc‘s (NASDAQ:AVGO) division Symantec announced a collaboration with Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) Google Cloud to boost generative AI-powered cybersecurity.

As per the deal, Google Cloud will integrate generative AI into the Symantec Security platform in a phased rollout manner to offer customers a strong technical edge to detect and eradicate cyber-attacks. This will result in increased security and higher SOC productivity.

AVGO has been a partner of Google Cloud for several years, which has helped accelerate its growth strategy. 

RelatedGoogle’s Power Move: Broadcom Ditched in Favor of Marvell Amid AI Chip Wars

“Symantec has a long history of designing, implementing, and fine-tuning artificial intelligence and machine learning for critical security use cases and helping our customers drive value out of AI. Our partnership with Google Cloud is part of that continuing journey to put the most innovative security solutions possible into user hands. Our engineers have simplified the process in ways that will enable customers to be much more productive and effective. This is just the beginning of a great collaboration that will help to kickstart the benefits of AI throughout the broader security ecosystem,” said Adam Bromwich, CTO and Head of Engineering, Symantec Enterprise Division.

Also ReadDespite Speculation of Google’s Shift, Analyst Sees Strong Ties and Momentum in Broadcom’s Decade-Long Partnership

Price Action: AVGO shares are trading lower by 1.97% at $817.44 on the last check Tuesday.

Total
0
Shares
Related Posts
Read More

Jounce Therapeutics Reports Results From Phase 2 Randomized SELECT Trial Testing 2 Different Doses Of Vopratelimab In TISvopra Biomarker-Selected Patients; Co. Reports Study Did Not Meet Its Primary Endpoint

- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks - - Encouraging trends in improved mean tumor

JNCE